Adagio Medical Holdings (ADGM) EBITDA (2023 - 2026)

Adagio Medical Holdings (ADGM) has 4 years of EBITDA data on file, last reported at -$7.0 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$7.0 million, up 9.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$24.4 million (down 36.4% YoY), and the FY2025 annual result was -$25.2 million, up 53.16% from the prior year.
• EBITDA fell to -$7.0 million in Q1 2026 per ADGM's latest filing, from -$3.3 million in the prior quarter.
• Over five years, EBITDA peaked at $3.6 million in Q3 2024 and troughed at -$10.8 million in Q3 2023.
• A 4-year average of -$6.2 million and a median of -$7.4 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA surged 133.44% in 2024, then tumbled 381.18% in 2025.
• A 4-year view of EBITDA shows it stood at -$8.6 million in 2023, then soared by 141.68% to $3.6 million in 2024, then tumbled by 192.02% to -$3.3 million in 2025, then sank by 112.66% to -$7.0 million in 2026.
• Business Quant data shows ADGM's EBITDA at -$7.0 million in Q1 2026, -$3.3 million in Q4 2025, and -$10.1 million in Q3 2025.